Human pluripotent stem cell-derived neural progenitor (hNP) cells are an excellent resource for understanding early neural development and neurodegenerative disorders. Given that many neurodegenerative disorders can be correlated with defects in the mitochondrial genome, optimal utilization of hNP cells requires an ability to manipulate and monitor changes in the mitochondria. Here, we describe a novel approach that uses recombinant human mitochondrial transcription factor A (rhTFAM) protein to transfect and express a pathogenic mitochondrial genome (mtDNA) carrying the G11778A mutation associated with Leber's hereditary optic neuropathy (LHON) disease, into dideoxycytidine (ddC)-treated hNPs. Treatment with ddC reduced endogenous mtDNA and gene expression, without loss of hNP phenotypic markers. Entry of G11778A mtDNA complexed with the rhTFAM was observed in mitochondria of ddC-hNPs. Expression of the pathogenic RNA was confirmed by restriction enzyme analysis of the SfaN1-digested cDNA. On the basis of the expression of neuron-specific class III beta-tubulin, neuronal differentiation occurred. Our results show for the first time that pathogenic mtDNA can be introduced and expressed into hNPs without loss of phenotype or neuronal differentiation potential. This mitochondrial gene replacement technology allows for creation of in vitro stem cell-based models useful for understanding neuronal development and treatment of neurodegenerative disorders.
INTRODUCTION
Many human neurodegenerative disorders containing defects in the mitochondrial genome are characterized by irrevocable damage and improper functions of specialized neuronal cells or populations. 1 For example, Leber's hereditary optic neuropathy (LHON) result from point mutations in mitochondrial DNA (mtDNA) that cause retinal ganglion neuron degeneration and blindness in young adults. 2, 3 Presence of other large mutations/deletions in mtDNA have been linked to other neurodevelopmental and age-related disorders. [4] [5] [6] Use of predictive and relevant cellular models would thus extensively benefit understanding many of these disorders, research needed to develop new drugs and novel therapeutic approaches.
The cytoplasmic hybrid cell, commonly known as cybrids, is an in vitro model in which donors' mtDNA, obtained from platelets, is expressed against tumorigenic nuclear backgrounds in host cells depleted of their endogenous mtDNA. Studies have shown that cybrids have been used to understand mtDNA-derived bioenergetic deficiencies in neurodegenerative disorders. [7] [8] [9] However, better models are needed to overcome both the glycolysis-preferring metabolism of tumor cells as hosts, and the mesodermal sources as platelets, used for cybrid creation that may not accurately reflect the genome inside the ectodermal-derived non-mitotic neural cells.
In this study, we introduced exogenous mtDNA containing the G11778A mutation, causal for LHON, into human pluripotent stem cell-derived neural progenitors (hNPs). The choice of the pathogenic mtDNA carrying the G11778A mutation associated with LHON in our study was primarily based on its ease of detection by restriction enzyme analysis after introduction into dideoxycytidine (ddC)-treated hNPs. hNPs are self-renewing stable cell lines that can be differentiated at will, along neuronal, astrocytic or oligodendroglial lineages. 1, [10] [11] [12] [13] These cell lines exhibit a normal karyotype and have also exhibited potential for genomic replacement studies 14 and as primary cell sources for assays of new therapeutics for neurodegenerative diseases. 15, 16 Human mitochondrial transcription factor A (TFAM) is a member of the high-mobility group of DNA-binding, and has been shown to be essential for mtDNA replication and transcription. [17] [18] [19] Recent studies have demonstrated the potential for a recombinant human TFAM protein engineered with an N-terminal protein transduction domain (PTD), followed by a mitochondrial leader sequence (MLS) to enter rapidly into the mitochondrial compartment of cybrid cells, using its 'mitochondrial transduction domain' (MTD¼PTD+MLS). 20 These encouraging results demonstrated that the human mitochondria could be manipulated from outside the cell, and provided the impetus for our current study in assessing the potential of MTD-TFAM in delivering and expressing exogenous mtDNA into hNPs.
To our knowledge, this is the first report describing mitochondrial genetic replacement of a self-renewing neural progenitor cell type. We demonstrate the introduction and expression of exogenous mtDNA in hNPs that have had their endogenous mtDNA reduced, and their potential for being maintained and subsequently differentiated into neurons.
RESULTS

Generation and characterization of ddC-treated hNPs
Stably propagating hNPs with reduced endogenous mtDNA is a necessary first step in generating in vitro mtDNA-based models. We initially assessed the response of hNPs to 2,3 ddC treatment and treated the hNPs for a period of 6 days in medium containing 10, 20, 60 and 100 mM of 2,3 ddC (Supplementary Figures 1a and b) . hNPs demonstrated a concentration-dependent loss in cell viability; compared with higher concentrations, 10 mM ddC-treated viable cells maintained neural rosette morphology ( Figure 1 and Supplementary  Figure 1a) . Maintenance of the neural rosette structures after 10-mM ddC treatment is a good indicator that the hNP structural phenotype was not altered. Further, during early neurogenesis, once the rosettes have matured and individual cells take on a columnar morphology, they robustly express nestin and musashi1. After 6 days of ddC exposure, immunocytochemistry confirmed equivalent positive nestin expression in the ddC-treated hNPs, compared with their controluntreated counterparts (Figure 1 ). Quantitative PCR (qPCR) analysis (Figure 2a and Supplementary Table 1) showed that levels of Sox2, nestin, fibronectin and musashi1, genes highly expressed in hNPs, 12 were the same in untreated and ddC-treated hNPs. Exposure to 10-mM ddC thus maintained viable cells without altering the representative hNP morphology or gene expression. ddC inhibits mitochondrial DNA polymerase gamma's ability to convert ddC to dideoxycytidine triphosphate 21, 22 and reduces mtDNA replication. We monitored the copy numbers of candidate mitochondrial genes (ND2, ND4 and COX3) in our ddC-hNP samples by qPCR analysis. Copy numbers for mtDNA-displacement loop (D-loop), and ND2, ND4 and COX3 genes (normalized to 18S rRNA) significantly decreased in ddC-hNPs (83% in D-loop, 75% in ND2, 72% in ND4, and 59% in COX3), indicating reduced endogenous mitochondrial genome content (Figure 2b ). We also observed that prolonged exposure of hNPs to ddC beyond 6 days extensively reduced cell viability. Thus, for the purposes of our study and in experiments detailed below, we decided to limit ddC exposure to 6 days before introduction of the exogenous mtDNA.
Entry of pathogenic LHON mtDNA into hNPs
We then extracted mtDNA from SH-SY5Y neuroblastoma cybrid cells carrying the G11778A mutation in the mtDNA ND4 gene from a patient afflicted with LHON. 2, 3 These cybrids were created in a SH-SY5Y rho0 cell line, by fusion with platelets from a 42-year-old male with LHON, which contained the pathogenic mtDNA in high abundance, and were a kind gift of Dr Russell Swerdlow. The G11778A mutation eliminates an SfaN1 site present in normal mtDNA ND4 gene, facilitating its detection with restriction digestion analysis.
MTD-TFAM protein was fluorescently labeled with Alexa488 dye according to manufacturer's instructions (Alexa Fluor 488 Protein Labeling Kit, Invitrogen, Carlsbad, CA, USA), and added to ddChNPs. Live cell confocal images revealed rapid entry of labeled MTD-TFAM into the mitochondrial compartment within the first 5 min (Supplementary Figure 2) . Next, we purified LHON mtDNA from LHON cybrids, labeled it with Cy3 dye according to manufacturer's instructions (Mirus, Madison, WI, USA), complexed it with unlabeled MTD-TFAM and added the mixture to ddC-hNPs. We observed slower entry of the Cy3-LHON mtDNA/MTD-TFAM complex over several hours that appears to be complete after 4-5 h ( Figure 3 ). Our results are consistent to what has been observed earlier in cybrid models, where 100% entry of MTD-TFAM was achieved within 40 min and persisted for 6 h. 20, 23 Further, the entry of the mtDNA/ MTD-TFAM complex was slower due to the size of the large complex, Figure 1 Immunocytochemical staining for nestin (green) and 4,6-diamidino-2-phenylindole (blue) in normal hNPs (bottom) and hNPs treated with 10 mM ddC for 6 days (top). Positive expression of nestin is maintained in hNPs after ddC treatment, indicating minimal alteration in characteristics of hNPs. The color reproduction of this figure is available at the Gene Therapy journal online.
and has been observed in cybrid lines irrespective of the mtDNA used (Iyer and Bennett, unpublished data).
Expression of pathogenic LHON RNA in hNPs
In independent experiments, we used restriction digestion analysis with SfaN1 to confirm the presence of LHON cDNA in transfected ddC-hNPs. As controls, we examined mtDNA from LHON cybrids and corresponding parental controls by PCR analysis, with primers designed around the ND4 region. Restriction digestion analysis revealed a B350-bp product, confirming the presence of the LHON mtDNA ( Figure 4a We then used SfaN1 restriction digestion analysis of cDNA to demonstrate the expression of the LHON mtDNA introduced after complexing with MTD-TFAM into ddC-hNPs. After 48 h of mtDNA introduction, we isolated total RNA from individual groups (untreated ddC-hNPs, MTD-TFAM introduced into ddC-hNPs, LHON mtDNA complexed with MTD-TFAM introduced into ddChNPs), reverse transcribed RNA into cDNA, and PCR amplified around the ND4 region. SfaN1 digestion analysis revealed a strong B350-bp band, along with the existence of the B255-and B108-bp band in ddC-hNPs treated with LHON mtDNA complexed with MTD-TFAM (Figure 4b 
Differentiation of LHON-hNPs
Following successful transfer of the LHON mtDNA into hNPs, we also investigated the differentiation potential of the manipulated hNPs. After 2 weeks of differentiation, the manipulated LHONhNPs formed extensive neurites, exhibited neuronal morphology, and positively stained for Tuj1 (bIII tubulin, neuronal marker) ( Figure 5 and Supplementary Video).
DISCUSSION
In this study, we directly introduced and expressed a LHON pathogenic mtDNA containing a G11778A mutation into a human multipotent stem cell that possesses the genomic and anatomic properties of a neural progenitor and a developmental precursor of non-mitotic neurons. This LHON-hNP line contains and expresses LHON mtDNA and also has the capacity of differentiating into neurons. The challenging aspect of this replacement was in creating a ddC-hNP line, without compromising the viability and the integrity of the hNP marker expression. On the basis of our experimental outcomes showing reduction of endogenous mtDNA and gene expression without loss of hNP gene expression, we have demonstrated a potential approach for creating mtDNA-depleted line in hNPs treated with ddC ( Figure 6 ).
Previous studies supporting the potential for mitochondrial genome replacement in stem cells have utilized different approaches in the murine and the non-human primate system. 24, 25 In the murine system, trans-mitochondrial embryonic stem (ES) cell lines were generated by fusion of cytoplasts carrying a variety of mtDNA mutations, into mouse ES cells that had been pretreated with rhodamine 6G, to prevent transmission of endogenous mtDNA. This study also demonstrated that neuronal differentiation could occur, although the differentiation was impaired in the stem cells carrying the mtDNA mutations that correlated with biochemical deficiencies. 24 Although this study demonstrated that the mitochondrial genome could be manipulated in ES cells that could further be differentiated into neurons, the use of fibroblasts in the cybrid-based approach may not accurately reflect the genome inside non-mitotic neural cells. We believe that the advantage provided by our approach is the ability to directly introduce and create hNPs carrying pathogenic mtDNA, whereas utilizing the parental hNP protein machinery for preserving and regulating the mitochondrial function.
In the non-human primate system, mitochondrial genome replacement was achieved in mature primate oocytes by a spindlechromosomal complex transfer from one egg to an enucleated, mitochondrial-replete egg. 25 The study showed that reconstructed oocytes with the mitochondrial replacement were capable of supporting normal fertilization, producing ES cell lines and healthy offspring. This approach has been proposed as an option for replacing the full complement of mitochondria in newly generated ES cell lines, but requires replacement in the primary oocyte stage. Although this approach proposed mitochondrial replacement, the end goal is an option to prevent mtDNA disease transmission in affected families. Due to the fact that this manipulation has to be carried out at the primary oocyte stage, this exciting therapeutic option might not lend itself to replacement of the mitochondrial genome in cell lines that could serve as models of complex neurodegenerative disorders, as shown in our current study.
In summary, mtDNA mutations contribute to a diverse range of neurological disorders, and generation of appropriate in vitro models that provide opportunities for mimicking specific diseases are necessary. We believe that the strength of our study lies in the simplicity of the experimental approach and in being able to manipulate the mitochondrial genome to introduce a pathogenic mtDNA into hNPs. Our novel approach provides enormous opportunities for generating relevant models that will aid in understanding and tracing the genesis of the disease as they progress forward. Defects in the mitochondrial genome contribute primarily to neuromuscular disorders, but have also been implicated in common neurodegenerative age-related disorders such as Parkinson's disease, Alzheimer's disease and amyotrophic lateral sclerosis. 4 Studies on mtDNA mutations in the context of these neurodegenerative disorders, their role on the fate and development of neurons, and their influence on the progress of complex diseases at the cellular level will contribute to improved understanding and therapeutic possibilities.
Our novel approach also provides opportunities for creating models that will aid in understanding the fundamental questions related to homoplasmy and transmission of a particular pathogenic mtDNA as the disease progresses. In our study, it is interesting to note that both species of mtDNA (LHON and normal) replicated and transcribed within 48 h in the ddC-hNPs post-treatment with the pathogenic mtDNA complexed with MTD-TFAM (Figure 3b ). What this result means in terms of continued replication and transcription of the pathogenic mtDNA in differentiated neurons, astrocytes and oligodendrocytes will be addressed in future studies ( Figure 6 ). Specifically, we will determine the changes in the mutant load, when cells differentiate, as studies have shown that mitochondrial biogenesis events trigger changes in mitochondrial mass and copy number during differentiation. 26 Additionally, our future studies will measure phenotypic differences (bioenergetics, oxidative stress, signaling pathway analysis) as a result of introduction of exogeneous mtDNA into hNPs and compare with cybrid-based observations. Although specific mutations like the G11778A mutation accounts for a vast majority of LHON cases in the Western world, recent identification of a different set of LHON disease-causing mutations 27 provides opportunities for assessing the importance of these novel mutations in our in vitro models. Further, development of these in vitro models that carry diverse mtDNA mutations will serve as excellent components of drugtesting platforms that could contribute to alleviation of symptoms associated with many mitochondrial and neurodegenerative disorders. Hence, we propose that outcomes from this study may represent a novel reliable approach to generate in vitro models in a dish for a wide range of human neurological disorders that have mutations in the mitochondrial genome.
MATERIALS AND METHODS hNP propagation and culture conditions
hNPs (Aruna Biomedical, Athens, GA, USA) were routinely cultured on polyornithine/laminin-coated 35-mm dishes or T-25 flasks, based on previously published protocols. 10, 12 Cells were propagated in neurobasal medium (Invitrogen) with B-27 supplements, leukemia inhibitory factor, basic fibroblast growth factor and antibiotics (penicillin and streptomycin). Cells were passaged at a sub-culturing ratio of 1:2 when 90-100% confluent, by scraping them off with a cell scraper.
Creation and characterization of ddC-treated hNPs
For reduction of endogenous mtDNA, hNPs were treated with 2¢,3¢ ddC, a potent inhibitor of mitochondrial DNA polymerase gamma for a period of 6 days. qPCR and immunocytochemical analyses were used to determine expression of mt-and hNP markers in ddC-treated hNPs. For immunocytochemical analysis for detection of nestin expression, cells plated on polyornithine/ laminin-coated permanox slides were washed in phosphate-buffered saline (PBS) and fixed with 4% paraformaldehyde/4% sucrose in PBS for 15 min. Fixed cells were washed two times with PBS before staining. Permeabilization and blocking was carried out in blocking buffer consisting of 0.1% Triton, 3% goat serum in Tris buffer for 40 min. Cells were incubated in blocking buffer containing (rabbit anti-nestin; 1:200; Millipore, Billerica, MA, USA) for 2 h at room temperature, followed by three washes in blocking buffer, before incubation in blocking buffer containing (goat anti-rabbit conjugated Alexa 488; 1:1000; Molecular Probes Inc., Eugene, OR, USA) for 40 min at room temperature. After two washes in PBS, cells were incubated for 10 min in 4,6-diamidino-2-phenylindole (nuclear stain) and observed under the fluorescence microscope. Controls involved removal of primary antibodies from the staining protocol.
qPCR analyses on ddC-treated hNPs was conducted to determine expression of mt (D-loop, ND2, ND4, COX3) and hNP markers (NES, MSI1, FN1, SOX2) as described previously. 20 Total genomic DNA and total RNA were isolated from cell pellets using All-Prep kits from Qiagen (Valencia, CA, USA) and amounts assayed with Quant-IT DNA and RNA assays (Invitrogen). Total RNA Figure 5 Immunocytochemical staining for Tuj1 (green) and 4,6-diamidino-2-phenylindole (blue) in 14-day differentiated neurons generated from ddC-treated hNPs, treated with LHON mtDNA complexed with MTD-TFAM. Positive expression of Tuj1 is an indication of neuronal differentiation potential of the LHON-hNPs. The color reproduction of this figure is available at the Gene Therapy journal online. of 1 mg was reverse transcribed into cDNA using iScript (BioRad, Hercules, CA, USA). Levels of 18S rRNA, mtDNA D-loop and hNP markers were assayed using SybrGreen detection (BioRad) with Roche human genomic DNA or a full-length mtDNA PCR product, respectively, as standards. 20 Copy numbers of ND2, COX3 and ND4 mitochondrial genes were assayed in a multiplex qPCR assay (BioRad Powermix) using the full-length PCR product of human mtDNA as standard. All reverse transcription qPCR was carried out in an iQ5 thermocycler (BioRad) using primers and probes designed with Beacon Designer software (PREMIER Biosoft International, Palo Alto, CA, USA). Levels of mitochondrial genes were normalized to 18S rRNA in either DNA or RNA (cDNA) samples. Data was obtained from three biological replicates, and statistical comparisons conducted using one-way analysis of variance to determine significant difference in gene expression values.
Production of MTD-TFAM, preparation of LHON mtDNA and introduction of LHON mtDNA into ddC-treated hNPs Purification and production of recombinant human MTD-TFAM was conducted as per previously published protocols. 20 Briefly, the MTD-TFAM was engineered to possess an N-terminal PTD containing 11 arginines, ligated to an SOD2 sequence for localization into the mitochondria (MLS). The final purified protein was stored in Tris-buffered 50% glycerol at À20 1C. DNA-binding capacity was assayed by electrophoretic mobility shift assay, based on maximum retardation of circular DNA. For all the experiments in this study, we have used a ratio of 500 ng of circular DNA complexed with 1 mg of MTD-TFAM.
LHON cybrid cells containing a 496% homoplasmic G11778A mutation in the ND4 region of mitochondrial genome were routinely propagated in Dulbecco's modified Eagle's medium containing 10% FCS. The LHON mtDNA was isolated by treating genomic DNA from LHON cybrid cells to limiting amounts of exonuclease and purified. 23, 28 The MTD-TFAM (+/À LHON mtDNA) mix was prepared by incubating the purified MTD-TFAM to 3 mg of LHON mtDNA in PBS containing high salt Mg 2+ buffer, at 37 1C for 30 min. The presence of the high salt Mg 2+ buffer was critical for facilitating protein binding to the DNA. hNPs were subsequently incubated in growth medium containing MTD-TFAM complexed with LHON mtDNA for two hours at 37 1C. Controls involved incubating the hNPs in growth medium containing only MTD-TFAM or PBS. After the incubation period, the medium was replaced with regular growth medium and the cells subjected to different experimental analyses as outlined below.
Imaging of LHON mtDNA entry into ddC-treated hNPs
For real-time imaging of LHON mtDNA entry into hNPs, cells were propagated to B80% confluence on laminin-coated 35 mm glass bottom dishes. The Figure 6 Proposed scheme outlining the steps involved in creation of neural progenitor cell model based on mitochondrial gene replacement. Red circles correspond to mitochondria containing endogenous mtDNA; white circles correspond to mitochondria depleted of their endogenous mtDNA and blue circles correspond to exogenous pathogenic mtDNA. The color reproduction of this figure is available at the Gene Therapy journal online.
Mitochondria in hNPs were stained using either Mitotraker red or Mitotracker Green (both from Mitosciences, Eugene, OR, USA) depending on whether tracking was being conducted for Alexa488-MTD-TFAM or Cy3 labeled LHON-mtDNA complexed with unlabeled MTD-TFAM respectively. MTD-TFAM was purified by dialyzing with 1ÂPBS buffer and labeled with Alexa 488 dye according to manufacturer's instructions (Invitrogen). Circular mtDNA carrying the LHON G11778A mutation was labeled using Cy3 dye according to manufacturer's instruction (Mirus, Madison, WI, USA). The labeled MTD-TFAM or the labeled LHON mtDNA complexed with MTD-TFAM was mixed in 2 ml Dulbecco's modified Eagle's medium and added to independent dishes of hNPs with labeled mitochondria. Real-time single plane-time lapse images were obtained every 5 min using an Olympus IX70 microscope (Olympus, Center Valley, PA, USA) with confocal capabilities.
Restriction enzyme digestion analysis
A PCR product in the ND4 gene spanning the SfaN1 site removed by the G11778A mutation was amplified from the cDNA of hNPs from independent treatments and digested with SfaN1 to check for the presence or absence of the mutation. Digested cDNA PCR products were analyzed using automated electrophoresis (Experion, BioRad).
Neuronal differentiation
The hNPs containing the LHON mtDNA were subjected to neuronal differentiation, based on published protocols. 10, 12 Briefly, the cells were allowed to attain 100% confluency in regular growth medium, after which the medium was replaced with medium lacking basic fibroblast growth factor and leukemia inhibitory factor for a period of 14 days. The neurons obtained were subjected to immunocytochemical analyses for beta-tubulin-III expression.
